Forwardly, Inc. Provides Shareholder Update
Forwardly Inc (OTCMKT: FORW) has provided key updates to shareholders. The company has withdrawn its S-1 filing under the 1934 Act following SEC objections, which requested filing under the 1940 Act. The decision was made due to the additional workload and expenses associated with the 1940 Act filing requirements.
The company's partner, Ligand Innovation Global, reports that their VitaCaeli G1 portable ventilator is approaching FDA approval in Nigeria and Ghana. Potential large orders of thousands of units are expected following approval, possibly during Q2 2025. However, Forwardly emphasizes these developments remain speculative and may not materialize.
Forwardly Inc (OTCMKT: FORW) ha fornito aggiornamenti importanti agli azionisti. L'azienda ha ritirato la sua registrazione S-1 ai sensi del 1934 Act a seguito delle obiezioni della SEC, che ha richiesto una registrazione ai sensi del 1940 Act. La decisione è stata presa a causa dell'ulteriore carico di lavoro e delle spese associate ai requisiti di registrazione del 1940 Act.
Il partner dell'azienda, Ligand Innovation Global, riporta che il loro VitaCaeli G1, un ventilatore portatile, sta per ricevere l'approvazione della FDA in Nigeria e Ghana. Si prevedono potenziali ordini di migliaia di unità dopo l'approvazione, possibilmente durante il secondo trimestre del 2025. Tuttavia, Forwardly sottolinea che questi sviluppi rimangono speculativi e potrebbero non concretizzarsi.
Forwardly Inc (OTCMKT: FORW) ha proporcionado actualizaciones clave a los accionistas. La empresa ha retirado su presentación S-1 bajo la Ley de 1934 tras las objeciones de la SEC, que solicitó la presentación bajo la Ley de 1940. La decisión se tomó debido a la carga de trabajo adicional y los gastos asociados con los requisitos de presentación de la Ley de 1940.
El socio de la empresa, Ligand Innovation Global, informa que su VitaCaeli G1, un ventilador portátil, está cerca de recibir la aprobación de la FDA en Nigeria y Ghana. Se esperan pedidos grandes de miles de unidades tras la aprobación, posiblemente durante el segundo trimestre de 2025. Sin embargo, Forwardly enfatiza que estos desarrollos siguen siendo especulativos y podrían no materializarse.
Forwardly Inc (OTCMKT: FORW)는 주주들에게 중요한 업데이트를 제공했습니다. 회사는 SEC의 이의 제기로 인해 1934년 법에 따른 S-1 제출을 철회했으며, SEC는 1940년 법에 따른 제출을 요청했습니다. 이 결정은 1940년 법에 따른 제출 요건과 관련된 추가 작업량 및 비용 때문입니다.
회사의 파트너인 Ligand Innovation Global는 그들의 VitaCaeli G1 휴대용 인공호흡기가 나이지리아와 가나에서 FDA 승인을 가까이 하고 있다고 보고했습니다. 승인 후 수천 대의 대규모 주문이 예상되며, 이는 2025년 2분기 중일 가능성이 있습니다. 그러나 Forwardly는 이러한 개발이 여전히 추측적이며 실현되지 않을 수 있음을 강조합니다.
Forwardly Inc (OTCMKT: FORW) a fourni des mises à jour importantes aux actionnaires. L'entreprise a retiré son dépôt S-1 en vertu de la loi de 1934 suite aux objections de la SEC, qui a demandé un dépôt en vertu de la loi de 1940. La décision a été prise en raison de la charge de travail supplémentaire et des frais associés aux exigences de dépôt de la loi de 1940.
Le partenaire de l'entreprise, Ligand Innovation Global, rapporte que leur VitaCaeli G1, un ventilateur portable, est en passe d'obtenir l'approbation de la FDA au Nigeria et au Ghana. Des commandes potentielles de milliers d'unités sont attendues après l'approbation, possiblement au cours du deuxième trimestre de 2025. Cependant, Forwardly souligne que ces développements restent spéculatifs et pourraient ne pas se concrétiser.
Forwardly Inc (OTCMKT: FORW) hat den Aktionären wichtige Updates bereitgestellt. Das Unternehmen hat seine S-1-Anmeldung gemäß dem Gesetz von 1934 zurückgezogen, nachdem die SEC Einwände erhoben hatte und eine Anmeldung gemäß dem Gesetz von 1940 verlangte. Die Entscheidung wurde aufgrund der zusätzlichen Arbeitsbelastung und der Kosten im Zusammenhang mit den Anforderungen der Anmeldung gemäß dem Gesetz von 1940 getroffen.
Der Partner des Unternehmens, Ligand Innovation Global, berichtet, dass ihr VitaCaeli G1 tragbares Beatmungsgerät kurz vor der FDA-Zulassung in Nigeria und Ghana steht. Nach der Genehmigung werden potenziell große Bestellungen von Tausenden von Einheiten erwartet, möglicherweise im zweiten Quartal 2025. Forwardly betont jedoch, dass diese Entwicklungen spekulativ bleiben und möglicherweise nicht eintreten.
- Potential approval of VitaCaeli G1 ventilator in Nigeria and Ghana
- Expected large orders of thousands of ventilator units in Q2 2025
- S-1 filing withdrawal due to SEC regulatory complications
- Additional regulatory burden and expenses under 1940 Act requirements
- Speculative nature of ventilator approval and orders
Henderson, NV and Toronto, ON, March 10, 2025 (GLOBE NEWSWIRE) -- George Sharp, CEO of Forwardly, Inc. (OTCMKT: FORW), provides the following updates to the company’s shareholders.
Due to the objections of the United States Securities and Exchange (“SEC”) regarding the company’s S-1 filing under the 1934 Act—the SEC has requested that Forwardly file under the 1940 Act—the company has elected to withdraw its S-1 filing for the time being. This is due to the burden of work and expense required to file under the 1940 Act. Forwardly expects that the circumstances under which the company is required to file under the 1940 Act may change during 2025, after which the company will be able to file under the 1934 Act.
Ligand Innovation Global, with whom Forwardly has partnered in the development of a portable ventilator, reports that its VitaCaeli G1 appears to be poised to be approved by the FDAs of Nigeria and Ghana with immediate large orders of thousands of units to follow. Ligand believes that this could be accomplished during the second quarter of 2025. However, as always, Forwardly cautions investors that the current situation is speculative and that these developments may not occur.
Forwardly continues to entertain additional partnerships with legitimate enterprises.
About Forwardly, Inc.
Forwardly is an opportunity investor seeking to partner in fresh ideas. The company is headed by George Sharp, a longtime whistleblower, advocate against microcap fraud, and defender of shareholder rights. In addition to his continued participation in these activities, Mr. Sharp consults to public companies, attorneys and those associated with the financial markets. He is also a former consultant to OTC Markets Group, Inc. Further information about Forwardly, Inc. can be obtained through its website at www.ForwardlyPlaced.com
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACT:
Forwardly, Inc.
3535 Executive Terminal Drive
Suite 110
Henderson, NV 89052
702-840-4433
FAQ
Why did Forwardly (FORW) withdraw its S-1 filing in March 2025?
When does Forwardly (FORW) expect to refile its S-1 under the 1934 Act?
What is the status of Ligand Innovation Global's VitaCaeli G1 ventilator project with FORW?
How many VitaCaeli G1 units are expected to be ordered after FDA approval?
